CRON Stock Overview
Cronos Group Inc. operates as a cannabinoid company.
No risks detected for CRON from our risk checks.
Cronos Group Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||CA$4.34|
|52 Week High||CA$11.37|
|52 Week Low||CA$3.65|
|1 Month Change||11.86%|
|3 Month Change||-3.34%|
|1 Year Change||-51.40%|
|3 Year Change||-79.00%|
|5 Year Change||76.42%|
|Change since IPO||422.89%|
Recent News & Updates
We Think Cronos Group (TSE:CRON) Can Afford To Drive Business Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
|CRON||CA Pharmaceuticals||CA Market|
Return vs Industry: CRON exceeded the Canadian Pharmaceuticals industry which returned -62.1% over the past year.
Return vs Market: CRON underperformed the Canadian Market which returned 4.9% over the past year.
|CRON Average Weekly Movement||9.2%|
|Pharmaceuticals Industry Average Movement||11.5%|
|Market Average Movement||9.9%|
|10% most volatile stocks in CA Market||16.9%|
|10% least volatile stocks in CA Market||4.3%|
Stable Share Price: CRON is not significantly more volatile than the rest of Canadian stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: CRON's weekly volatility (9%) has been stable over the past year.
About the Company
Cronos Group Inc. operates as a cannabinoid company. It manufactures, markets, and distributes hemp-derived supplements and cosmetic products through e-commerce, retail, and hospitality partner channels under the Lord Jones and Happy Dance brands in the United States. The company is also involved in the cultivation, manufacture, and marketing of cannabis and cannabis-derived products for the medical and adult-use markets.
Cronos Group Fundamentals Summary
|CRON fundamental statistics|
Is CRON overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|CRON income statement (TTM)|
|Cost of Revenue||US$94.50m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.71|
|Net Profit Margin||-307.35%|
How did CRON perform over the long term?See historical performance and comparison
Is Cronos Group undervalued compared to its fair value and its price relative to the market?
Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: CRON (CA$4.34) is trading above our estimate of fair value (CA$2.12)
Significantly Below Fair Value: CRON is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: CRON is unprofitable, so we can't compare its PE Ratio to the Canadian Pharmaceuticals industry average.
PE vs Market: CRON is unprofitable, so we can't compare its PE Ratio to the Canadian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate CRON's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: CRON is good value based on its PB Ratio (1x) compared to the CA Pharmaceuticals industry average (1.1x).
How is Cronos Group forecast to perform in the next 1 to 3 years based on estimates from 11 analysts?
Future Growth Score2/6
Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CRON is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: CRON is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: CRON is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: CRON's revenue (38% per year) is forecast to grow faster than the Canadian market (6.4% per year).
High Growth Revenue: CRON's revenue (38% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: CRON is forecast to be unprofitable in 3 years.
How has Cronos Group performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CRON is currently unprofitable.
Growing Profit Margin: CRON is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: CRON is unprofitable, and losses have increased over the past 5 years at a rate of 16.2% per year.
Accelerating Growth: Unable to compare CRON's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CRON is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (134.7%).
Return on Equity
High ROE: CRON has a negative Return on Equity (-20.26%), as it is currently unprofitable.
How is Cronos Group's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: CRON's short term assets ($1.1B) exceed its short term liabilities ($40.3M).
Long Term Liabilities: CRON's short term assets ($1.1B) exceed its long term liabilities ($9.4M).
Debt to Equity History and Analysis
Debt Level: CRON is debt free.
Reducing Debt: CRON has no debt compared to 5 years ago when its debt to equity ratio was 7.8%.
Debt Coverage: CRON has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: CRON has no debt, therefore coverage of interest payments is not a concern.
What is Cronos Group current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate CRON's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CRON's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CRON's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CRON's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as CRON has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mike Gorenstein (34 yo)
Mr. Michael Ryan Gorenstein, also known as Mike, J.D., serves as the Chairman of Cronos Group Inc. since March 21, 2022 and served as its Executive Chairman since September 09, 2020 until March 21, 2022 an...
CEO Compensation Analysis
Compensation vs Market: Mike's total compensation ($USD389.15K) is below average for companies of similar size in the Canadian market ($USD2.24M).
Compensation vs Earnings: Mike's compensation has been consistent with company performance over the past year.
Experienced Management: CRON's management team is not considered experienced ( 0.8 years average tenure), which suggests a new team.
Experienced Board: CRON's board of directors are considered experienced (3.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Cronos Group Inc.'s employee growth, exchange listings and data sources
- Name: Cronos Group Inc.
- Ticker: CRON
- Exchange: TSX
- Founded: 2012
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: CA$1.630b
- Shares outstanding: 375.58m
- Website: https://www.thecronosgroup.com
Number of Employees
- Cronos Group Inc.
- 111 Peter Street
- Suite 300
- M5V 2H1
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/22 00:00|
|End of Day Share Price||2022/05/20 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.